Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.35 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21132542 | 0.91 | MAP2K1 (0.44) | LMNAALDH1A1KDM4ESPRMAPT | |
| SCHEMBL18519079 | 0.85 | LMNA (0.39) | TP53LMNAPOLBGAATDP1 | |
| SCHEMBL18518674 | 0.83 | MAP2K1 (0.45) | — | |
| SCHEMBL18518790 | 0.81 | MAP2K1 (0.36) | TP53POLBGAATDP1ALDH1A1 | |
| SCHEMBL13063536 | 0.81 | MAP2K1 (0.52) | — | |
| SCHEMBL18518668 | 0.79 | MAP2K1 (0.40) | ALDH1A1KDM4EMAPTKMT2ACYP1A2 | |
| SCHEMBL2719489 | 0.76 | MAP2K1 (0.39) | — | |
| SCHEMBL5553673 | 0.76 | MAP2K1 (0.44) | LMNASPR | |
| SCHEMBL18518815 | 0.75 | MAP2K1 (0.41) | LMNAKMT2ACYP1A2 | |
| SCHEMBL2718528 | 0.75 | MAP2K1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190177335-A1 | METHOD FOR PREPARING INTERMEDIATE OF 6-ARYLAMINOPYRIDONECARBOXAMIDE COMPOUND AS MEK INHIBITOR | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177335-A1 | METHOD FOR PREPARING INTERMEDIATE OF 6-ARYLAMINOPYRIDONECARBOXAMIDE COMPOUND AS MEK INHIBITOR | MAPK6, MAP3K6, BRAF | TP53 2768/4885LMNA 1064/4885POLB 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.